SCHEMBL6521944

SCHEMBL6521944

O=C(Nc1ccccc1)Nc1ccc(CCl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
EPHX1 P07099 2/20 0.65
TSHR P16473 1/20 0.65
EPHX2 P34913 1/20 0.65
CDK9 P50750 1/20 0.65
CLK4 Q9HAZ1 1/20 0.65
CASP3 P42574 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
MAOA P21397 2/20 0.60
MAOB P27338 2/20 0.60
HIF1A Q16665 2/20 0.58
RAB9A P51151 7/20 0.58
NPC1 O15118 6/20 0.58
KMT2A Q03164 5/20 0.58
TAAR1 Q96RJ0 3/20 0.58
POLB P06746 1/20 0.56
SIRT1 Q96EB6 1/20 0.56
MAPT P10636 4/20 0.55
MEN1 O00255 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5069026 0.89 MEN1 (0.54) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL2891493 0.84 SMN1; SMN2 (0.71) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL29200398 0.84 MEN1 (0.62) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL30802678 0.84 MEN1 (0.62) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL29200426 0.83 MEN1 (0.72) TP53SMN1; SMN2TSHRRAB9ANPC1
SCHEMBL11059378 0.83 SMN1; SMN2 (0.94) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL2817203 0.82 SMN1; SMN2 (0.68) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL5852104 0.82 SMN1; SMN2 (0.68) TP53SMN1; SMN2EPHX1TSHREPHX2
SCHEMBL7100059 0.82 RAB9A (0.61) SMN1; SMN2RAB9ANPC1KMT2AMAPT
SCHEMBL29200415 0.82 NTRK1 (0.54) SMN1; SMN2MAOAMAOBNPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117658868-A Benzamide derivative and preparation method and application thereof 中山大学 2024-03-08 CN disclosed
US-20110053947-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-03-03 US disclosed
EP-1183241-B1 SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM AVENTIS PHARMA GMBH (DE) 2003-09-17 EP disclosed
US-6399643-B1 ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-06-04 US disclosed
EP-1183241-A1 SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2002-03-06 EP disclosed
WO-2000069831-A1 SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053947-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof PGC, LIPC, CEL TP53 4633/4885SMN1; SMN2 4875/4885EPHX1 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.